Estetrol prevents Western diet-induced obesity and atheroma independently of hepatic estrogen receptor α.
Adipose Tissue
/ pathology
Animals
Diet, Western
/ adverse effects
Estetrol
/ administration & dosage
Estrogen Receptor alpha
/ genetics
Female
Glucose Tolerance Test
Hepatocytes
/ metabolism
Lipids
/ blood
Liver
/ metabolism
Mice
Mice, Inbred C57BL
Mice, Knockout
Obesity
/ pathology
Ovariectomy
Plaque, Atherosclerotic
/ pathology
Receptors, LDL
/ genetics
atherosclerosis
estrogen receptor
fatty liver
menopause
metabolic syndrome
Journal
American journal of physiology. Endocrinology and metabolism
ISSN: 1522-1555
Titre abrégé: Am J Physiol Endocrinol Metab
Pays: United States
ID NLM: 100901226
Informations de publication
Date de publication:
01 01 2021
01 01 2021
Historique:
pubmed:
3
11
2020
medline:
9
2
2021
entrez:
2
11
2020
Statut:
ppublish
Résumé
Estetrol (E4), a natural estrogen synthesized by the human fetal liver, is currently evaluated in phase III clinical studies as a new menopause hormone therapy. Indeed, E4 significantly improves vasomotor and genito-urinary menopausal symptoms and prevents bone demineralization. Compared with other estrogens, E4 was found to have limited effects on coagulation factors in the liver of women allowing to expect less thrombotic events. To fully delineate its clinical potential, the aim of this study was to assess the effect of E4 on metabolic disorders. Here, we studied the pathophysiological consequences of a Western diet (42% kcal fat, 0.2% cholesterol) in ovariectomized female mice under chronic E4 treatment. We showed that E4 reduces body weight gain and improves glucose tolerance in both C57Bl/6 and
Identifiants
pubmed: 33135461
doi: 10.1152/ajpendo.00211.2020
doi:
Substances chimiques
Estrogen Receptor alpha
0
Lipids
0
Receptors, LDL
0
Estetrol
ENB39R14VF
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM